[N03AX03, sulthiame, The risk or severity of liver damage can be increased when Tetracosactide is combined with Sulthiame.]
[N05CA19, thiopental, The risk or severity of liver damage can be increased when Tetracosactide is combined with Thiopental.]
[N03AC02, trimethadione, The risk or severity of liver damage can be increased when Tetracosactide is combined with Trimethadione.]
[N03AX21, ezogabine, The risk or severity of liver damage can be increased when Tetracosactide is combined with Ezogabine.]
[N03AX14, levetiracetam, The risk or severity of liver damage can be increased when Tetracosactide is combined with Levetiracetam.]
[N05CA04, barbital, The risk or severity of liver damage can be increased when Tetracosactide is combined with Barbital.]
[N03AX22, perampanel, The risk or severity of liver damage can be increased when Tetracosactide is combined with Perampanel.]
[N03AF04, eslicarbazepine, The risk or severity of liver damage can be increased when Tetracosactide is combined with Eslicarbazepine.]
[N03AG04, vigabatrin, The risk or severity of liver damage can be increased when Tetracosactide is combined with Vigabatrin.]
[S01EC01, acetazolamide, The risk or severity of liver damage can be increased when Tetracosactide is combined with Acetazolamide.]
[N03AX23, brivaracetam, The risk or severity of liver damage can be increased when Tetracosactide is combined with Brivaracetam.]
[N02BF02, pregabalin, The risk or severity of liver damage can be increased when Tetracosactide is combined with Pregabalin.]
[N03AX30, beclamide, The risk or severity of liver damage can be increased when Tetracosactide is combined with Beclamide.]
[N03AF01, carbamazepine, The risk or severity of liver damage can be increased when Tetracosactide is combined with Carbamazepine.]
[N03AX24, cannabidiol, The risk or severity of liver damage can be increased when Tetracosactide is combined with Cannabidiol.]
[N03AX17, stiripentol, The risk or severity of liver damage can be increased when Tetracosactide is combined with Stiripentol.]
[N06AX29, brexanolone, The risk or severity of liver damage can be increased when Tetracosactide is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of liver damage can be increased when Tetracosactide is combined with Clobazam.]
[N03AX25, cenobamate, The risk or severity of liver damage can be increased when Tetracosactide is combined with Cenobamate.]
[N03AG02, dipropylacetamide, The risk or severity of liver damage can be increased when Tetracosactide is combined with Valpromide.]
[N05CM02, chlormethiazole, The risk or severity of liver damage can be increased when Tetracosactide is combined with Clomethiazole.]
[N06BX18, vinpocetine, The risk or severity of liver damage can be increased when Tetracosactide is combined with Vinpocetine.]
[N03AX10, felbamate, The risk or severity of liver damage can be increased when Tetracosactide is combined with Felbamate.]
[N02BF01, gabapentin, The risk or severity of liver damage can be increased when Tetracosactide is combined with Gabapentin.]
[N03AE01, clonazepam, Tetracosactide may increase the hepatotoxic activities of Clonazepam.]
[C04AX28, ifenprodil, The risk or severity of liver damage can be increased when Tetracosactide is combined with Ifenprodil.]
[N03AX09, lamotrigine, The risk or severity of liver damage can be increased when Tetracosactide is combined with Lamotrigine.]
[N03AG06, tiagabine, The risk or severity of liver damage can be increased when Tetracosactide is combined with Tiagabine.]
[N03AF02, oxcarbazepine, The risk or severity of liver damage can be increased when Tetracosactide is combined with Oxcarbazepine.]
[N03AC01, paramethadione, The risk or severity of liver damage can be increased when Tetracosactide is combined with Paramethadione.]
[N05BA01, diazepam, The risk or severity of liver damage can be increased when Tetracosactide is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of liver damage can be increased when Tetracosactide is combined with Phenacemide.]
[N03AD02, phensuximide, The risk or severity of liver damage can be increased when Tetracosactide is combined with Phensuximide.]
[N03AG05, progabide, The risk or severity of liver damage can be increased when Tetracosactide is combined with Progabide.]
[N07XX02, riluzole, The risk or severity of liver damage can be increased when Tetracosactide is combined with Riluzole.]
[N03AX11, topiramate, The risk or severity of liver damage can be increased when Tetracosactide is combined with Topiramate.]
[N03AX15, zonisamide, The risk or severity of liver damage can be increased when Tetracosactide is combined with Zonisamide.]
[N05CD04, estazolam, The risk or severity of liver damage can be increased when Tetracosactide is combined with Estazolam.]
[N03AD01, ethosuximide, The risk or severity of liver damage can be increased when Tetracosactide is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of liver damage can be increased when Tetracosactide is combined with Ethotoin.]
[N03AX26, fenfluramine, The risk or severity of liver damage can be increased when Tetracosactide is combined with Fenfluramine.]
[N07CA03, flunarizine, The risk or severity of liver damage can be increased when Tetracosactide is combined with Flunarizine.]
[N03AA04, barbexaclone, The risk or severity of liver damage can be increased when Tetracosactide is combined with Barbexaclone.]
[N03AD03, methsuximide, The risk or severity of liver damage can be increased when Tetracosactide is combined with Methsuximide.]
[N05CA16, hexobarbital, The risk or severity of liver damage can be increased when Tetracosactide is combined with Hexobarbital.]
[M03BX02, tizanidine, The risk or severity of liver damage can be increased when Tetracosactide is combined with Tizanidine.]
[N03AX18, lacosamide, The risk or severity of liver damage can be increased when Tetracosactide is combined with Lacosamide.]
[N05BA06, lorazepam, The risk or severity of liver damage can be increased when Tetracosactide is combined with Lorazepam.]
[V04CC02, magnesium sulfate, The risk or severity of liver damage can be increased when Tetracosactide is combined with Magnesium sulfate.]
[N05BA03, medazepam, The risk or severity of liver damage can be increased when Tetracosactide is combined with Medazepam.]
[N03AB04, mephenytoin, The risk or severity of liver damage can be increased when Tetracosactide is combined with Mephenytoin.]
[N03AA01, mephobarbital, The risk or severity of liver damage can be increased when Tetracosactide is combined with Methylphenobarbital.]
[N03AA30, metharbital, The risk or severity of liver damage can be increased when Tetracosactide is combined with Metharbital.]
[N05CA15, methohexital, The risk or severity of liver damage can be increased when Tetracosactide is combined with Methohexital.]
[N03AF03, rufinamide, The risk or severity of liver damage can be increased when Tetracosactide is combined with Rufinamide.]
[N05CA02, amobarbital, The risk or severity of liver damage can be increased when Tetracosactide is combined with Amobarbital.]
[N03AB05, fosphenytoin, Tetracosactide may increase the hepatotoxic activities of Fosphenytoin.]
[N05CD02, nitrazepam, The serum concentration of Nitrazepam can be increased when it is combined with Tetracosactide.]
[N05CF03, zaleplon, The risk or severity of liver damage can be increased when Tetracosactide is combined with Zaleplon.]
[N05CC05, paraldehyde, The risk or severity of liver damage can be increased when Tetracosactide is combined with Paraldehyde.]
[N05CA01, pentobarbital, The risk or severity of liver damage can be increased when Tetracosactide is combined with Pentobarbital.]
[N03AA02, phenobarbital, The risk or severity of liver damage can be increased when Tetracosactide is combined with Phenobarbital.]
[N03AB02, phenytoin, Tetracosactide may increase the hepatotoxic activities of Phenytoin.]
[N03AA03, primidone, The risk or severity of liver damage can be increased when Tetracosactide is combined with Primidone.]
[N05CA06, secobarbital, The risk or severity of liver damage can be increased when Tetracosactide is combined with Secobarbital.]
[N03AG01, valproic acid, Tetracosactide may increase the hepatotoxic activities of Valproic acid.]
